Literature DB >> 7451435

Purification and properties of dihydrothymine dehydrogenase from rat liver.

T Shiotani, G Weber.   

Abstract

Rat liver dihydrothymine dehydrogenase, the rate-limiting enzyme of thymidine and uridine degradation, was purified to homogeneity as judged by polyacrylamide disc gel electrophoresis, sedimentation velocity, and Ultrogel ACA-34 elution profile. The enzyme has a molecular weight of 220,000 +/- 5,000 as determined by Ultrogel ACA-34 and sedimentation equilibrium The s20,w value of the enzyme was 9.2 S. The isoelectric point was at pH 5.25. The enzyme is composed of two identical subunits of an approximate molecular weight of 110,000 +/- 3,000 as determined by sodium dodecyl sulfate disc gel electrophoresis. The enzyme contains 4 mol of FAD and 3 mol of iron per mol of enzyme. Flavin released from the enzyme by boiling was identified as FAD by absorption spectra and thin layer chromatography, indicating that the enzyme is a flavometal protein. During dialysis, the enzyme was stabilized by 2-mercaptoethanol, but neither NADPH nor thymine was effective. The relative rates of reduction of pyrimidine analogues substituted at position 5 were 5-fluorouracil > 5-bromouracil > 5-diazouracil > 5-iodouracil > 5-nitrouracil, with 5-fluorouracil and 5-diazouracil 70% faster than thymine. Uracil was reduced 25% faster than thymine. The pH optimum for the forward and reverse reactions was 7.4. In the presence of NADPH, the apparent Km was 2.6 microM for thymine and 1.8 microM for uracil. Apparent Km for NADPH was 15 microM with thymine as substrate and 11 microM with uracil. In the reverse reaction, apparent Km values were 43 microM for dihydrothymine and 193 microM for dihydrouracil; apparent Km for NADP+ was 3.8 microM with dihydrothymine as substrate and 2.9 microM with dihydrouracil.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7451435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  A new case of dihydropyrimidine dehydrogenase deficiency.

Authors:  M Brockstedt; C Jakobs; L M Smit; A H van Gennip; R Berger
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors.

Authors:  M Tuchman; R F O'Dea; M L Ramnaraine; B L Mirkin
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

3.  Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.

Authors:  André B P van Kuilenburg; Doreen Dobritzsch; Rutger Meinsma; Janet Haasjes; Hans R Waterham; Malgorzata J M Nowaczyk; George D Maropoulos; Guido Hein; Hermann Kalhoff; Jean M Kirk; Holger Baaske; Anne Aukett; John A Duley; Kate P Ward; Ylva Lindqvist; Albert H van Gennip
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

4.  Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.

Authors:  D Dobritzsch; G Schneider; K D Schnackerz; Y Lindqvist
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

5.  Identification of fungal dihydrouracil-oxidase genes by expression in Saccharomyces cerevisiae.

Authors:  Jonna Bouwknegt; Aurin M Vos; Raúl A Ortiz Merino; Daphne C van Cuylenburg; Marijke A H Luttik; Jack T Pronk
Journal:  Antonie Van Leeuwenhoek       Date:  2022-10-14       Impact factor: 2.158

6.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Metabolic breakdown of [3H]thymidine and the inability to measure human lymphocyte proliferation by incorporation of radioactivity.

Authors:  J Bodycote; S Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 8.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 9.  DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report.

Authors:  Theodore J Wigle; Elena V Tsvetkova; Stephen A Welch; Richard B Kim
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.